DNM activity is required for optimal MK migration. (A) Migration patterns of tracked CHRF cells without or with DNM knockdown on FN toward an SDF-1α gradient in the microfluidics-based µ-slide chemotaxis assay. (B) Quantification of directional migration of CHRF cells. ShDNM2 and shDNM3 CHRF cells exhibited a reduced directional migration toward an SDF-1α gradient (P < .005). (C) Schematic representation of the treatment of CD34⁺ cell-derived human primary MKs. Before transwell migration assays, we differentiated human primary MKs from cord blood CD34⁺ cells, which we would treat with shDNM2 or DNSR. (D) Quantification of MK migration in transwells toward a chemoattractant (SDF-1α) gradient, with the effect of DNSR. Migration was decreased by ∼45% in DNSR-treated MKs vs control (CTRL; paired Student t test P < .001). (E) Quantification of MK migration in transwells toward a chemoattractant (SDF-1α) gradient, with the effect of DNM2 knockdown. Migration was decreased by approximately half in shDNM2-treated MKs vs CTRL (paired Student t test P < .01). Error bars indicate standard errors of the mean of ≥3 independent experiments. *P ≤ .05, **P ≤ .01.